Kronos Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.88 USD (At close: Jun 20, 2025) · Market cap 53.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease. The company was incorporated in 2017 and is headquartered in San Mateo, California. As of June 20, 2025, Kronos Bio, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Details
| Name | Kronos Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 10 |
| Founded | 2017 |
| Ipo Date | 2020-10-09 |
| Ceo | Deborah Knobelman |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 19.00 |
| Isin | US50107A1043 |
| Cusip | 50107A104 |
| Cik | 1741830 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Deborah A. Knobelman Ph.D. | Interim Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and President |
| Joshua A. Kazam | Co-Founder and Director |
| David M. Tanen J.D. | Secretary and Director |
Contact
| Address | 1300 So. El Camino Real, Suite 400, San Mateo, California 94402, United States |
| Phone | 650 781 5200 |
| Website | https://www.kronosbio.com |